Overview

Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction

Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
0
Participant gender:
All
Summary
The present study is designed to confirm the therapeutic effects of heat-clearing and blood-activating Chinese medicinal components in treatment of Acute Cerebral Infarction (ACI) and to investigate the therapeutic mechanisms of multi-target anti-inflammatory action involved from the standpoint of pathology, cell and molecular biology, as well as immunology.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yunling Zhang
Collaborators:
Huairou Hospital of Traditional Chinese Medicine
Shandong University of Traditional Chinese Medicine
Wuqing Hospital of Traditional Chinese Medicine
Criteria
Inclusion Criteria:

- Patients with acute ischemic stroke

- Patients with fire-heat syndrome

- Stroke onset within 48 hours

- NIHSS scores range from 5 points to 25 points

- Age from forty to eighty,gender not limited

- Informed and signed the consent

Exclusion Criteria:

- Cardiogenic cerebral embolism,stroke caused by other reasons or the unexplained

- Patients suitable for thrombolytic therapy(rt-PA,urokinase),or have recieved
thrombolytic therapy

- Patients suitable for endovascular therapy,or have recieved endovascular therapy

- Patients with serious disease of heart,lungs,liver or kidneys(The value of ALT or AST
is more than 2 times of the upper limit of normal range,the value of creatinine is
more than 1.5 times of the upper limit of normal range,asthma or COPD,or cardiac
function level 4)

- Patients with bleeding or bleeding tendency recently

- Pregnant or lactating women

- Pre-existing limb dysfunction, psychiatric diaseses,or cognitive dysfunction that
could confound the study results

- Patients with allergic constitutions,or have the contraindication of Ixeris of
sonchifolia Hance components(KDZ injection) or Panax notoginseng saponins
components(Xueshuantong injection)

- Patients have participated in other clinical trials within 3 months